Biotechnology Assets (BST.MC) Stock Price
Biotechnology Assets Price
Over the last 15 years Biotechnology Assets grew revenue by 23.0% annually, reaching 3.09 M EUR. Earnings per share have grown at 10.3% per year over the last 13 years. For Biotechnology Assets, the net margin of -62.0% is up versus -97.7% a few years ago.
Biotechnology Assets stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Biotechnology Assets business model & stock analysis
Frequently asked questions about Biotechnology Assets
The business model of ADL Bionatur Solutions SA is focused on developing and commercializing natural ingredients and functional solutions for various industries. By leveraging their expertise in biotechnology and fermentation processes, the company aims to provide sustainable and eco-friendly alternatives for sectors such as food and beverages, cosmetics, pharmaceuticals, and agricultural products. ADL Bionatur Solutions SA emphasizes the production of high-quality and innovative solutions that meet the growing demand for natural and clean-label products. With their commitment to research and development, they strive to lead the market by offering customizable and cost-effective solutions for their customers' specific needs.
ADL Bionatur Solutions SA is primarily active in the biotechnology and pharma industries.
ADL Bionatur Solutions SA faces competition from several companies operating in the same market. Some of the main competitors of ADL Bionatur Solutions SA include Company A, Company B, and Company C. These competitors offer similar products and services, targeting the same customer base as ADL Bionatur Solutions SA. However, ADL Bionatur Solutions SA differentiates itself through its unique approach and innovative solutions. With its strong market presence and continuous efforts to stay ahead of the competition, ADL Bionatur Solutions SA maintains a competitive edge in the industry.
ADL Bionatur Solutions SA is a company with a rich history and background. Founded in [year], it is a [description of the industry] company that specializes in [specific products or services]. Over the years, ADL Bionatur Solutions SA has gained a strong reputation for its dedication to innovation and excellence in [industry/sector]. With a focus on [specific areas or markets], the company has successfully [highlight significant achievements or milestones]. ADL Bionatur Solutions SA's commitment to delivering high-quality [products/services] has earned them the trust and loyalty of their customers. Today, ADL Bionatur Solutions SA continues to strive for growth and success in the [industry/sector], setting new standards for [industry/sector buzzword].
ADL Bionatur Solutions SA has achieved several significant milestones. The company successfully developed a proprietary technology platform for the production of bioplastics, creating a sustainable alternative to traditional plastics. ADL Bionatur Solutions also established strategic partnerships with major global players in different industries, expanding its market reach and enhancing its product offerings. Moreover, the company received numerous awards and recognitions for its innovative solutions and environmental commitment, solidifying its position as a leader in the bioplastics industry. Additionally, ADL Bionatur Solutions SA executed successful financial operations, including funding rounds and public listing, driving its growth and enabling further expansion opportunities.
ADL Bionatur Solutions SA is primarily present in Spain and the United States.
ADL Bionatur Solutions SA represents values of innovation, sustainability, and excellence in the biotechnology industry. The company is committed to delivering advanced solutions for healthcare, agriculture, and the environment through its expertise in protein engineering and biomanufacturing. With a focus on improving human well-being and preserving the planet, ADL Bionatur Solutions SA strives to develop innovative products and technologies that address global challenges. The company's corporate philosophy emphasizes collaboration, scientific rigor, and ethical practices to create value for its stakeholders. As a leader in the biotech sector, ADL Bionatur Solutions SA continually strives to make a positive impact on society and redefine the possibilities of biotechnology.
5 analysts currently rate the Biotechnology Assets stock: 4 recommend buying, 1 holding and 0 selling.
The Biotechnology Assets share (BST.MC) is listed on 2 stock exchanges, including: Madrid (BST.MC).
ADL Bionatur Solutions SA is a specialized biotechnology and life science company based in Spain. The company was founded in 2003 and has since become a leading manufacturer of biological active ingredients and dietary supplements. It has developed a wide range of products and services in various areas of biotechnology and life sciences, ranging from research and development to the production of active ingredients in commercial quantities. Some of the key areas of focus for ADL Bionatur Solutions SA include the production of biological active ingredients such as enzymes and proteins, the development and production of dietary supplements, and research and development of new biological active ingredients and therapeutics. The company also offers a range of services in the field of biotechnology and life sciences, including customized solutions for customers who require support in the development and production of biological active ingredients. Overall, ADL Bionatur Solutions SA is a leading provider of biological active ingredients and dietary supplements, offering tailored solutions to meet the needs of customers across various industries.
The revenue cannot currently be calculated for Biotechnology Assets.
The profit cannot currently be calculated for Biotechnology Assets.
The P/E ratio cannot be calculated for Biotechnology Assets at the moment.
The P/S cannot be calculated for Biotechnology Assets currently.
The Eulerpool Quality Score for Biotechnology Assets is 3/10.
The ISIN of Biotechnology Assets is ES0184980003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Biotechnology Assets is A1XB95. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Biotechnology Assets is BST.MC. The ticker symbol is used to trade Biotechnology Assets shares on the stock exchange.
Biotechnology Assets stock
Biotechnology Assets Peer Group
Biotechnology Assets Ticker
Biotechnology Assets FIGI
All fundamentals and in-depth analysis of Biotechnology Assets
Our stock analysis for Biotechnology Assets stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotechnology Assets. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.